MIPI Calculator

Understanding the Mantle Cell Lymphoma International Prognostic Index (MIPI)

Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin lymphoma characterized by monoclonal B-cell proliferation and cyclin D1 overexpression. Prognosis among patients with advanced mantle cell lymphoma varies widely. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is the primary validated clinical risk-stratification tool developed by the European MCL Network to categorize patient risk and guide clinical management.

MIPI and Biological MIPI (MIPI-b) Mathematical Formulas

The standard simplified MIPI score incorporates four independent prognostic factors: age, Eastern Cooperative Oncology Group (ECOG) performance status, white blood cell (WBC) count, and serum lactate dehydrogenase (LDH) levels normalized to the upper limit of normal (ULN):

$$\text{MIPI} = 0.03535 \times \text{Age} + 0.6978 \text{ (if ECOG 2-4)} + 1.367 \times \log_{10}(\text{WBC}) + 0.9393 \times \log_{10}\left(\frac{\text{LDH}}{\text{ULN}}\right)$$

The Biological MIPI (MIPI-b) incorporates tumor cell proliferation by adding the Ki-67 proliferation index percentage:

$$\text{MIPI-b} = \text{MIPI} + 0.0214 \times \text{Ki-67 (\% convexity)}$$

Risk Stratification & Clinical Prognosis

Patients are stratified into three distinct risk categories based on their calculated MIPI score:

• Low Risk (Score < 5.7): Median overall survival is not reached (> 5 years), with an estimated 5-year overall survival rate of approximately 60%.
• Intermediate Risk (5.7 ≤ Score < 6.2): Median overall survival is approximately 51 months, with a 5-year overall survival rate of around 36%.
• High Risk (Score ≥ 6.2): Median overall survival is approximately 29 months, with a 5-year overall survival rate of around 26%.

For other oncology risk and early warning tools, explore our MEWS Score Calculator or Metastatic Prostate Cancer Prognosis Calculator.